We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+30.37%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$558M
AUM Growth
+$201M
Cap. Flow
+$128M
Cap. Flow %
22.94%
Top 10 Hldgs %
67.51%
Holding
90
New
30
Increased
23
Reduced
7
Closed
26

Top Buys

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$51.2M
2
INDP icon
Indaptus Therapeutics
INDP
+$15M
3
KDMN
Kadmon Holdings, Inc.
KDMN
+$9.52M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$4.24M
5
NVTA
Invitae Corporation
NVTA
+$4.06M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$12.2M
2
KITE
Kite Pharma, Inc.
KITE
+$7.78M
3
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
+$5.12M
4
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$4.57M
5
ANAB icon
AnaptysBio
ANAB
+$3.96M

Sector Composition

Rank Sector Weight
1 Healthcare 46.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TCRT icon
76
PUT
Alaunos Therapeutics
TCRT
$4.66M
– –
-1,000
Closed -$933K
VCYT icon
77
CALL
Veracyte
VCYT
$3.58B
– –
-160,000
Closed -$1.33M
SCTL
78
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
– –
-223,558
Closed -$1.41M
IMGN
79
CALL
DELISTED
Immunogen Inc
IMGN
– –
-50,000
Closed -$356K
ARAV
80
PUT
DELISTED
Aravive, Inc. Common Stock
ARAV
– –
-8,183
Closed -$857K
ACOR
81
PUT
DELISTED
Acorda Therapeutics
ACOR
– –
-250
Closed -$591K
CLVS
82
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-20,000
Closed -$1.59M
AERI
83
PUT
DELISTED
Aerie Pharmaceuticals
AERI
– –
-40,000
Closed -$2.1M
TSRO
84
DELISTED
TESARO, Inc.
TSRO
– –
-23,700
Closed -$3.31M
JUNO
85
PUT
DELISTED
Juno Therapeutics, Inc.
JUNO
– –
-80,000
Closed -$2.39M
KITE
86
DELISTED
Kite Pharma, Inc.
KITE
– –
-75,000
Closed -$7.78M
WBMD
87
DELISTED
WebMD Health Corp.
WBMD
– –
-33,000
Closed -$1.94M
SPNC
88
PUT
DELISTED
Spectranetics Corp
SPNC
– –
-40,000
Closed -$1.54M
NDRM
89
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
– –
-72,866
Closed -$2.18M
NDRM
90
PUT
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
– –
-10,000
Closed -$299K
1 2 3
4

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q3 2017 Portfolio in Review

As of Q3 2017, Acuta Capital Partners held 90 positions worth $558M, up 56% from $357M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Acuta Capital Partners deployed $128M of net new capital in Q3 2017, opening 30 new positions and adding to 23 existing holdings. Its largest new stake was Kadmon Holdings, Inc.: 3,333,333 shares worth $11.2M.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, down from 60% a quarter earlier.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $12.2M trimmed.

  • Acuta Capital Partners's largest Q3 2017 buy was Kadmon Holdings, Inc.: 3,333,333 shares worth $11.2M.
  • Acuta Capital Partners added most to Immunomedics Inc in Q3 2017, an estimated $51.2M increase.
  • Acuta Capital Partners's biggest Q3 2017 reduction was Ascendis Pharma A/S, cutting an estimated $12.2M.
  • Acuta Capital Partners fully exited Kite Pharma, Inc. in Q3 2017, selling an estimated $7.78M.
  • Acuta Capital Partners's ten largest holdings make up 68% of its $558M portfolio in Q3 2017.
  • Acuta Capital Partners opened 30 new positions and closed 26 in Q3 2017.
  • Acuta Capital Partners's portfolio value rose 56% quarter-over-quarter to $558M.

Based on Acuta Capital Partners's 13F filing for Q3 2017, filed 14 Nov 2017.